



INVESTOR PRESENTATION
Quarterly Update

Q4 2023





Forward Looking Information

This presentation contains “forward-looking information” within the meaning of applicable securities laws. Forward looking information may relate to our future outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategy, budgets, operations, financial results, taxes, dividend policy, plans, intentions, beliefs, and objectives of our Company. Particularly, information regarding our expectations of future results, performance, achievements, prospects or opportunities is forward looking information. In some cases, forward looking information can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects”, “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward looking information. Statements containing forward looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. In addition, our assessments of, and targets for, annual revenue, Adjusted EBITDA, Adjusted diluted earnings per share and certain other measures are considered forward looking information. See the section titled “Outlook” in our most recently filed MD&A for additional information concerning our strategies, assumptions and market outlook related to these assessments.

The forward-looking information contained in this presentation is based on management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe to be appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Certain assumptions in respect of the ability to pursue further strategic acquisitions; our ability to source raw materials and other inputs from our suppliers; our ability to continue to innovate product offerings that resonate with our target customer base; our ability to retain key management and personnel; our ability to continue to expand our international presence and grow our brand internationally; our ability to obtain and maintain existing financing on acceptable terms; currency exchange and interest rates; the impact of competition; changes to trends in our industry or global economic factors; and changes to laws, rules, regulations and global standards are material factors made in preparing the forward looking information and management’s expectations contained in this presentation.

The forward-looking information contained in this presentation represents management’s expectations as of the date of this presentation and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that management considered appropriate and reasonable as of the date such statements are made, is subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to those described under the heading “Risk Factors” in our 2023 annual MD&A for the fiscal year ended December 31, 2023 and in our most recent annual information form.

We caution that the list of risk factors and uncertainties under the heading “Risk Factors” is not exhaustive and other factors could also adversely affect our results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

NON-IFRS FINANCIAL MEASURES

This presentation may make reference to the following non IFRS financial measures: “EBITDA”, “Adjusted EBITDA”, “Adjusted net earnings”, “normalized gross profit”, “normalized SG&A”, “normalized earnings from operations”, “cash from operating activities before working capital considerations” and “net debt”, the following non-IFRS ratios: “Adjusted EBITDA margin”, “Adjusted diluted earnings per share”, “normalized gross profit margin”, “normalized operating margin”, and the following supplementary financial measures: “gross profit margin”, “operating margin” and “USD denominated revenue”, to provide supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. For further details on these non-IFRS measures, non-IFRS ratios, and supplementary financial measures, including relevant definitions and certain reconciliations, see our most recently filed MD&A.



2023 Year in Review Highlights



Shanghai Headquarters
Opening, April 2023



Jamieson Campaign in Jordan,
August 2023



- 1 Expanded leadership position in Canada driven by strong dollar and unit consumption growth outpacing the market, despite customer level inventory adjustments
 - Consumers continued to interact with the Company's immune products and increase their purchases across foundational health categories including, sleep, stress and energy
- 2 Successful implementation of growth strategy in the U.S. delivered approximately 17.4% pro forma revenue growth, driven by innovation and category growth, e-commerce expansion, and increased distribution
- 3 Delivered 45.1% pro forma revenue growth in China as a result of the completion of the Company's acquisition of its former distributor's assets and strategic partnership with DCP Capital as well as continued consumer demand in cross border e-commerce and growth in domestic retail
- 4 Growth in the back half of the year within International markets despite global volatility; consumer consumption trends began a return to historical levels in Eastern Europe
- 5 Finalized the Company's annual ESG reporting strategy and implemented a new environmental policy



Fourth Quarter 2023 Highlights




- 1 Record-high consumer consumption and shipments drove increased market share in Canada despite retailer level inventory sell through beyond expectation
- 2 Growth of the youtheory brand in the U.S led by strong demand for existing products, innovation, progress in e-commerce as well as new distribution
- 3 Demand in China was further strengthened in cross border e-commerce with a strong 11/11 promotion window and expanded distribution in brick-and-mortar retail
- 4 Revenue growth in International was partially offset by volatility in the Middle East
- 5 Completed the Company's 2023 greenhouse gas inventory report for disclosure in the Company's first formal Impact Report in Q1 2024
- 6 Exited the quarter with a leverage ratio of approximately 2.1x net debt to Adjusted EBITDA with cash and available borrowings of over \$200.0 million

Fourth Quarter 2023 Summary of Segment Results

- Revenue was **\$181.0 million**, an increase of **16.0%** or **\$25.0 million**



Canada
revenue
increased
5.8% to
\$94.3 million



U.S. (youtheory)
contributed
\$55.0 million
in revenue

Increasing by **8.7%**,
local currency basis
of **9.0%**



China
revenue
increased
151.1% to
\$20.7 million

Proforma and local
currency basis: **91.6%**



International
revenue
increased
37.0%¹ to
\$11.1 million

¹on a constant USD basis

- Gross profit increased **\$7.7 million** to **\$73.1 million**; gross profit margin decreased by **150 bps** largely driven by sales mix
- Adjusted EBITDA¹ increased **\$1.6 million** to **\$45.4 million**

¹ This is a non-IFRS financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS financial measure.



STRATEGIC PARTNERS

Fourth Quarter 2023 Summary of Segment Results

- Revenue was **\$39.4 million**, an increase of **7.0%** or **\$2.6 million**
- Gross profit increased **\$0.1 million** to **\$5.9 million**
- Gross profit margin¹ decreased by **80 basis points** to **15.1%** with production efficiencies and pricing offset by customer mix
- Adjusted EBITDA² increased by **\$0.2 million** to **\$5.2 million**;
Adjusted EBITDA margin³ decreased by **40 basis points** to **13.3%**

¹ This is a supplementary financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each supplementary financial measure.

² This is a non-IFRS financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS financial measure.

³ This is a non-IFRS ratio. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS ratio.



Fourth Quarter 2023

Balance Sheet and Cash Flow

- Cash from operating activities before working capital considerations of **\$20.4 million** decreased by **\$8.7 million** compared to Q4 2022
- Cash from working capital decreased by **\$6.0 million** mainly driven by the timing of vendor and income tax payments made
- Cash flows used in investing activities decreased by **\$0.1 million**; purchases of property, plant and equipment were consistent with the prior quarter
- Cash flows used in financing activities totaled **\$9.9 million**
- As of December 31, 2023, the Company had **\$211.9 million** in cash and available revolving and swingline facilities and net debt of **\$288.1 million**



Fourth Quarter 2023 Consolidated Results

| METRIC | Q4 2023 | Q4 2022 | Growth Rate |
|-------------------------------------|---------|---------|--|
| Total Revenue | \$220.4 | \$192.8 | 14.3% |
| Jamieson Brands Segment | | | |
| Canada | \$94.3 | \$89.1 | 5.8% |
| U.S. (youtheory) | \$55.0 | \$50.6 | 8.7% reported, 9.0% local currency |
| China | \$20.7 | \$8.2 | 151.1% reported, 91.6% proforma & local currency |
| International | \$11.0 | \$8.0 | 37.0% local currency |
| Total Jamieson Brands Segment | \$181.0 | \$156.0 | 16.0% |
| Strategic Partners Segment | \$39.4 | \$36.8 | 7.0% |
| Adjusted EBITDA | \$50.6 | \$48.9 | 3.6% |
| Adjusted EBITDA Margin ¹ | 23.0% | 25.4% | (2.4%) |
| Adjusted diluted EPS | \$0.67 | \$0.62 | 8.1% |

¹ Adjusted EBITDA margin decreased by 240 basis points to 23.0% for the quarter as we prioritized certain SG&A and marketing investment in the U.S. and China.

Summary Consolidated Financial Information



| (\$ in millions, except as otherwise noted) | Fiscal Year Ended December 31, | | | | |
|--|-----------------------------------|--------------|--------------|--------------|--------------|
| | 2023 | 2022 | 2021 | 2020 | 2019 |
| Revenue | 676.2 | 547.4 | 451.0 | 403.7 | 345.0 |
| Cost of sales | 442.6 | 349.0 | 288.6 | 258.9 | 215.2 |
| Selling, general and administrative expenses | 140.3 | 110.2 | 80.7 | 76.3 | 69.9 |
| Share-based compensation | 5.9 | 4.9 | 5.7 | 4.9 | 4.3 |
| Acquisition related adjustments | (7.9) | -- | -- | -- | -- |
| Earnings from operations | 95.3 | 83.2 | 76.0 | 63.6 | 55.4 |
| Foreign exchange loss (gain) | 2.0 | 0.3 | (0.1) | 0.5 | 0.4 |
| Other expenses | -- | -- | -- | 0.0 | 3.4 |
| Interest expense and other financing costs | 22.8 | 12.4 | 5.7 | 6.0 | 9.4 |
| Accretion on preferred shares | 4.8 | -- | -- | -- | -- |
| Earnings before income taxes | 65.7 | 70.5 | 70.5 | 57.0 | 42.3 |
| Provision for income taxes | 19.6 | 17.7 | 18.4 | 15.5 | 10.6 |
| Net earnings | 46.0 | 52.8 | 52.1 | 41.6 | 31.7 |
| Revenue | 676.2 | 547.4 | 451.0 | 403.7 | 345.0 |
| Adjusted EBITDA | 138.1 | 123.8 | 100.1 | 88.0 | 75.9 |
| Adjusted EBITDA Margin | 20.4% | 22.6% | 22.2% | 21.8% | 22.0% |
| Adjusted Net Earnings | 66.1 | 65.1 | 55.2 | 47.9 | 38.1 |
| Adjusted Net Earnings Per Fully Diluted Share | 1.55 | 1.55 | 1.32 | 1.16 | 0.96 |

Summary Consolidated Financial Information



| | Three Months Ended December 31, | | | Twelve Months Ended December 31, | | |
|--|------------------------------------|--------------|---------------|-------------------------------------|--------------|----------------|
| | 2023 | 2022 | % Change | 2023 | 2022 | % Change |
| <i>(\$ in millions, except as otherwise noted)</i> | | | | | | |
| Revenue | 220.4 | 192.8 | 14.3% | 676.2 | 547.4 | 23.5% |
| Cost of sales | 141.3 | 121.6 | 16.2% | 442.6 | 349.0 | 26.8% |
| Gross profit margin | 35.9% | 36.9% | (1.0%) | 34.5% | 36.2% | (1.7%) |
| Selling, general and administrative expenses | 42.3 | 32.8 | 29.1% | 140.3 | 110.2 | 27.3% |
| Acquisition related adjustments | (7.9) | - | (100.0%) | (7.9) | - | (100.0%) |
| Share-based compensation | 1.5 | 1.3 | 16.5% | 5.9 | 4.9 | 19.5% |
| Earnings from operations | 43.1 | 37.1 | 16.0% | 95.3 | 83.2 | 14.5% |
| Foreign exchange loss | 1.7 | 1.0 | 71.4% | 2.0 | 0.3 | 629.4% |
| Interest expense and other financing costs | 4.9 | 5.8 | (15.1%) | 22.8 | 12.4 | 83.5% |
| Accretion on preferred shares | 2.0 | - | 100.0% | 4.8 | - | 100.0% |
| Income before income taxes | 34.5 | 30.4 | 13.7% | 65.7 | 70.5 | (6.9%) |
| Provision for income taxes | 10.5 | 8.3 | 27.2% | 19.6 | 17.7 | 10.9% |
| Net earnings | 24.0 | 22.1 | 8.6% | 46.0 | 52.8 | (12.8%) |
| Revenue | 220.4 | 192.8 | 14.3% | 676.2 | 547.4 | 23.5% |
| Adjusted EBITDA | 50.6 | 48.9 | 3.6% | 138.1 | 123.8 | 11.6% |
| Adjusted EBITDA Margin | 23.0% | 25.4% | (2.4%) | 20.4% | 22.6% | (2.2%) |
| Adjusted Net Earnings | 28.6 | 26.8 | 6.9% | 66.1 | 65.1 | 1.4% |
| Adjusted Earnings Per Share | 0.67 | 0.62 | 8.1% | 1.55 | 1.55 | 0.0% |

Reconciliation of net income to EBITDA, adjusted EBITDA and adjusted net income



| (\$ in millions, except as otherwise noted) | Three Months Ended | | Fiscal Year Ended | | | | | |
|---|--------------------|-------------|-------------------|--------------|--------------|-------------|-------------|-------------|
| | December 31, | | December 31, | | | | | |
| | 2023 | 2022 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
| Net earnings | 24.0 | 22.1 | 46.0 | 52.8 | 52.1 | 41.6 | 31.7 | 26.7 |
| Provision for income taxes | 10.5 | 8.3 | 19.6 | 17.7 | 18.4 | 15.5 | 10.6 | 10.6 |
| Interest expense and other financing costs | 4.9 | 5.8 | 22.8 | 12.4 | 5.7 | 6.0 | 9.4 | 9.0 |
| Accretion on preferred shares | 2.0 | -- | 4.8 | -- | -- | -- | -- | -- |
| Depreciation and amortization | 5.1 | 5.1 | 20.3 | 17.2 | 14.3 | 12.2 | 10.9 | 9.0 |
| EBITDA | 46.5 | 41.2 | 113.6 | 100.2 | 90.4 | 75.3 | 62.6 | 55.3 |
| Share-based compensation | 1.5 | 1.3 | 5.9 | 4.9 | 5.7 | 4.9 | 4.3 | 3.1 |
| Foreign exchange loss | 1.7 | 1.0 | 2.0 | 0.3 | (0.1) | 0.5 | 0.4 | 0.6 |
| Acquisition and divestiture related costs | 2.8 | 3.2 | 8.4 | 12.9 | -- | -- | -- | -- |
| Amortization of fair value adjustments | 2.6 | 0.8 | 8.4 | 0.8 | -- | -- | -- | -- |
| COVID-19 related costs | -- | -- | -- | 0.2 | 2.4 | 5.1 | -- | -- |
| IT implementation and business integration | 3.3 | 1.4 | 7.7 | 4.5 | 1.9 | 2.2 | 1.2 | 4.1 |
| International market expansion | -- | -- | -- | -- | -- | -- | 1.7 | 0.9 |
| Acquisition related purchase consideration and post-closing adjustments | (7.9) | -- | (7.9) | -- | -- | -- | -- | -- |
| Other | 0.0 | -- | (0.1) | -- | (0.1) | -- | 0.0 | 0.0 |
| Adjusted EBITDA | 50.6 | 48.9 | 138.1 | 123.8 | 100.1 | 88.0 | 75.9 | 67.6 |
| Provision for income taxes | (10.5) | (8.3) | (19.6) | (17.7) | (18.4) | (15.5) | (10.6) | (10.6) |
| Interest expense and other financing costs | (4.9) | (5.8) | (22.8) | (12.4) | (5.7) | (6.0) | (9.4) | (9.0) |
| Depreciation and amortization | (5.1) | (5.1) | (20.3) | (17.2) | (14.3) | (12.2) | (10.9) | (9.0) |
| Share-based compensation | (1.4) | (1.3) | (5.5) | (6.3) | (5.5) | (4.3) | (3.6) | (2.5) |
| Tax deduction from vesting of certain share-based awards | -- | -- | (1.0) | -- | -- | -- | (1.0) | -- |
| Other | -- | -- | -- | -- | -- | 0.1 | 0.2 | -- |
| Tax effect of normalization adjustments | (0.1) | (1.7) | (2.8) | (4.9) | (1.1) | (2.1) | (2.4) | (2.7) |
| Adjusted net earnings | 28.6 | 26.8 | 66.1 | 65.1 | 55.2 | 47.9 | 38.1 | 33.7 |
| Adjusted EBITDA | 50.6 | 48.9 | 138.1 | 123.8 | 100.1 | 88.0 | 75.9 | 67.6 |
| Less capital expenditures | 2.8 | 2.6 | 8.8 | 13.9 | 21.5 | 11.3 | 9.0 | 10.9 |
| Simple free cash flow | 47.8 | 46.3 | 129.2 | 109.8 | 78.6 | 76.7 | 66.9 | 56.7 |
| Simple free cash flow conversion | 94% | 95% | 94% | 89% | 79% | 87% | 88% | 84% |

Financial Performance: 2024 Guidance



| METRIC | 2023 | 2024 TARGET RANGE | GROWTH RATE | 2025 TARGET |
|---|---------|-------------------|-------------------|---------------|
| Total Revenue | \$676.2 | \$720.0 - \$760.0 | 6.5% - 12.5% | - |
| Jamieson Brands Segment | | | | |
| • Canada | \$314.1 | \$326.0 - \$338.0 | 4.0% - 7.5% | - |
| • U.S. (youtheory) | \$152.3 | \$172.0 - \$183.0 | 13.0% - 20.0% | - |
| • China | \$51.3 | \$82.0 - 92.0 | 60.0% - 80.0% | - |
| • International | \$33.5 | \$35.0 - \$39.0 | 5.0% - 15.0% | - |
| Total Jamieson Brands Segment | \$551.2 | \$615.0 - \$650.0 | 12.0% - 18.0% | 10% - 15% |
| Strategic Partners Segment ¹ | \$125.0 | \$100.0 - \$113.0 | (-10.0% - -20.0%) | - |
| Adj. EBITDA | \$138.1 | \$138.0 - \$144.0 | Up to ~4.5% | \$155 - \$165 |
| Adj. EBITDA Margin ² | 20.4% | - | -120 and -170 bps | - |
| Adj. Diluted Earnings per Share | \$1.55 | \$1.55 - \$1.65 | Up to ~6.5% | - |

¹ Strategic Partners expected to decline 10% to 20% driven by the impact of a 2023 customer transition partially offset by new partner programs scheduled for the second half

² Adjusted EBITDA margin expected to decline by 120 and 170 basis due to the impact of investments to drive growth in the U.S. and China as well as temporary lower Strategic Partners volumes and associated manufacturing efficiencies

This outlook reflects the following assumptions:

- Normalized SG&A including marketing expenses are expected to increase 20% to 35% based on relative investments in traditional SG&A (excl. marketing) of approximately 8% to 10%.
- Interest expense of \$19.0 to \$21.0 million based on our estimated borrowing and prevailing rates
- Income tax rates of approximately 28% based on non-deductible stock-based compensation and excluding the impact of preferred share interest accretion
- A fully diluted share count of approximately 42.5 million shares
- Average annual exchange rate between the U.S. and Canadian dollar of U.S. \$1.00 to 1.35
- Average annual exchange rate between the Chinese renminbi and the Canadian dollar of ¥1.00 to \$0.20.

*Company guidance updated on March 13, 2024

*All figures in millions except the purchase date



INVESTOR RELATIONS CONTACT:

Ruth Winker
rwinker@jamiesonlabs.com

 [linkedin.com/company/jamiesonwellness](https://www.linkedin.com/company/jamiesonwellness)

 twitter.com/JWEL_Canada

